This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Janssen Pharmaceutica Nv, Janssen Biotech, Inc.. Active years: 2020-2024.
Company Filing History:
Years Active: 2020-2024
Title: The Innovative Journey of Inventor Diana Chin
Introduction
Diana Chin, an accomplished inventor based in Norwood, Pennsylvania, has made significant contributions to the field of biotechnology. With three patented innovations to her name, she has focused her work on the development of antibodies that play a crucial role in targeting cancer-related proteins. Her latest patents exemplify her commitment to advancing medical science and improving treatment options for cancer patients.
Latest Patents
Diana Chin's most recent patents include groundbreaking work on anti-GPRC5D antibodies and bispecific antigen-binding molecules that target GPRC5D and CD3. These patents detail antibodies that specifically bind to GPRC5D, as well as related polynucleotides capable of encoding these antibodies or antigen-binding fragments. The technologies described not only encompass methods for diagnosing, treating, or monitoring GPRC5D-expressing cancer but also provide insight into determining suitable treatment protocols for patients. The versatility of these antibodies enables their use in assessing cancer progression, regression, or stability, thus providing essential tools for oncologists in their therapeutic approaches.
Career Highlights
Throughout her career, Diana has worked with prominent organizations such as Janssen Pharmaceutica NV and Janssen Biotech, Inc. Her experiences in these reputable companies have played a vital role in her research and development efforts. Diana's work is characterized by an unwavering dedication to finding innovative solutions to complex medical challenges.
Collaborations
In her journey as an inventor, Diana has collaborated with notable colleagues, including Ricardo Attar and Francois Gaudet. These partnerships have fostered an environment of shared knowledge and expertise, enhancing the scope and impact of her innovations.
Conclusion
Diana Chin’s contributions to the field of biotechnology through her patented innovations demonstrate her commitment to improving cancer treatment and patient outcomes. With her latest advancements in GPRC5D-targeting antibodies, she continues to pave the way for new therapeutic strategies. Her collaborations and experiences mark her as a significant figure in the realm of research and innovation, inspiring future inventors and scientists.